Institute for Quality and Efficiency in Health Care

Added benefit of vedolizumab is not proven

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Oct 23, 2014
popularity not rated yet | comments 0

Dimethyl fumarate for MS: Added benefit is not proven

Dimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for adults with relapsing remitting multiple sclerosis (RRMS). In an early benefit assessment pursuant to the Act on the Reform of the Market ...

Aug 07, 2014
popularity not rated yet | comments 0